       Document 0499
 DOCN  M9620499
 TI    Primary structure of the V3 region of gp120 from sequential human
       immunodeficiency virus type 1 isolates obtained from patients from the
       time of seroconversion.
 DT    9602
 AU    Distler O; McQueen PW; Tsang ML; Evans LA; Hurren L; Byrne C; Penny R;
       Cooper DA; Delaney SF; Department of Biotechnology, University of New
       South Wales,; Australia.
 SO    J Infect Dis. 1995 Nov;172(5):1384-7. Unique Identifier : AIDSLINE
       GENBANK/U17480
 AB    V3 loop sequences were compared from 5 human immunodeficiency virus type
       1 (HIV-1)-infected patients over time. Three patients remained
       asymptomatic and 2 became symptomatic with large decrease in CD4 cell
       counts. The patient isolates were previously evaluated for phenotypic
       and antigenic properties and had different sensitivities to serum
       neutralization and changes in phenotype. This study showed a number of
       amino acid changes for the 2 symptomatic patients, each of whom
       progressed to AIDS during the study. The only amino acid substitution
       consistently associated with reduced CD4 cell counts, cytopathic effect,
       and progression to AIDS was Arg at position 11. Specific amino acid
       changes could not be correlated with increasing serum neutralization
       resistance or cytotropism changes. Increased loop charge was associated
       with a switch from macrophage to T cell tropism and a decrease in the
       number of CD4 cells. The study shows the importance of naturally
       occurring mutations in the V3 loop in controlling the biologic
       properties of HIV-1.
 DE    Acquired Immunodeficiency Syndrome/IMMUNOLOGY/VIROLOGY  Amino Acid
       Sequence  Comparative Study  Consensus Sequence  DNA, Complementary
       Homosexuality, Male  Human  HIV Envelope Protein
       gp120/BIOSYNTHESIS/*CHEMISTRY/GENETICS  HIV
       Seropositivity/IMMUNOLOGY/*VIROLOGY  HIV-1/*GENETICS/ISOLATION & PURIF
       Male  Molecular Sequence Data  Polymerase Chain Reaction  RNA,
       Viral/GENETICS/ISOLATION & PURIF  Time Factors  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

